Skip to main content

At 22.2% CAGR, Next-Generation Sequencing Market Size [2021-2028] | To Reach USD 31,411.3 Million

Key Companies in Next-Generation Sequencing Market are Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, BGI, PerkinElmer Inc., Eurofins Scientific, Macrogen, Inc., PierianDx

Pune, India, Dec. 14, 2021 (GLOBE NEWSWIRE) — The global next-generation sequencing market size is expected to gain momentum by reaching USD 31,411.3 million by 2026 while exhibiting a CAGR of 22.2% between 2019 to 2026. In its report titled “Next Generation Sequencing Market, 2019-2026.”, Fortune Business Insights mentions that the market stood at USD 6,335.2 million in 2018. The rising demand for cost-effective and accurate DNA sequencing to treat genetic diseases is expected to drive the market. Moreover, the launch of several genomic projects in countries such as Qatar and the U.K with able support from the government is expected to fuel the market in upcoming years.

Industry Developments

January 2019:  PierianDx announced its partnership with Illumina to come up with informatics services such as oncology products for Illumina to support cancer diagnosis and research.


Request for Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/next-generation-sequencing-ngs-market-101000


Driving Factors

Growing Focus on Diagnosis of Diseases Globally to Augment Growth

Lower costs of sequencing solutions have resulted in the high demand for the diagnosis of several diseases. For instance, as per a new scientific paper published in the European Journal of Human Genetics, around 300 million people globally suffer from a rare genetic disease. Companies are focusing on the introduction of various test kits such as genetic testing, prenatal testing, and cancer diagnosis.

For instance, in May 2018, the Centers for Medicare & Medicaid Services (CMS) declared the National Coverage Determination to perform an NSG test to diagnose cancer. In addition, government reimbursement programs for diagnostic tests and approval of several NSG tools is expected to boost the global next-generation sequencing market growth during the forecast period.


To get to know more about the short-term and long-term impact of COVID-19 on this market
Please Visit: https://www.fortunebusinessinsights.com/industry-reports/next-generation-sequencing-ngs-market-101000


Market Segmentation:

Based on product type, the global market for next-generation sequencing is divided into instrument & software, consumables, and services. On the basis of application, the market is divided into diagnostics and research. By its end-user, the market is divided into research institutes, healthcare facilities, diagnostic centers, pharmaceutical and biotechnological companies, and contract research organizations. Finally, based on region, the market is categorized into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Regional Insights

North America to Remain Dominant; Presence of Major Biotech Companies to Aid Growth

North America is expected to hold the largest global next-generation sequencing market share during the forecast period. This is ascribable to factors such as the presence of supportive government policies and presence of major biotech companies and research labs. Moreover, the growing incidence of chronic disease is expected to boost the demand for the product in the region. For instance, In September 2018, the FDA approved marketing for ClonoSEQ assay, a NSG diagnostic test for the minimal residual disease (MRD), in patients suffering from acute lymphoblastic leukemia (ALL) or multiple myeloma. North America stood at USD 3.82 billion in 2020.

Asia Pacific is anticipated to hold a significant market share owing to the increasing awareness regarding well-being of reproductive health that will favor the adoption of the next-generation sequencing solutions in the region.


Quick Buy – Next-Generation Sequencing Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/101000


Key Players to Focus on Establishing Partnerships to Intensify Competition

The market is consolidated by the presence of major companies that are striving to maintain their position by focusing on acquisitions and establishing partnerships. For instance, in June 2019, Saphetor partnered with Swift Biosciences Inc. to speed up and standardize data interpretation solutions for targeted next-generation sequencing panels. Moreover, other key players are adopting proactive strategies such as new product launches, mergers, and facility expansion to favor the market’s growth in the forthcoming years.


List of the Key Players Profiled in the Global Market for Next-Generation Sequencing:

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • QIAGEN
  • BGI
  • PerkinElmer Inc.
  • Eurofins Scientific
  • Macrogen, Inc.
  • PierianDx


Ask For Customization: https://www.fortunebusinessinsights.com/enquiry/customization/next-generation-sequencing-ngs-market-101000


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.


Contact Us:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.